Trade AstraZeneca PLC - GBP - AZNl CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.26 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.025261% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003343% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | GBP | ||||||||
Margin | 5% | ||||||||
Stock exchange | United Kingdom of Great Britain and Northern Ireland | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
AstraZeneca PLC ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 101.97 |
Open* | 102.07 |
1-Year Change* | -5.24% |
Day's Range* | 101.61 - 102.19 |
52 wk Range | 97.78-123.92 |
Average Volume (10 days) | 2.37M |
Average Volume (3 months) | 41.29M |
Market Cap | 161.29B |
P/E Ratio | 34.98 |
Shares Outstanding | 1.55B |
Revenue | 35.41B |
EPS | 2.97 |
Dividend (Yield %) | 2.24885 |
Beta | 0.32 |
Next Earnings Date | Feb 8, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 18, 2024 | 101.97 | -0.92 | -0.89% | 102.89 | 102.95 | 101.97 |
Mar 15, 2024 | 102.73 | -0.54 | -0.52% | 103.27 | 104.73 | 102.65 |
Mar 14, 2024 | 103.97 | -0.46 | -0.44% | 104.43 | 104.75 | 103.73 |
Mar 13, 2024 | 104.27 | 0.14 | 0.13% | 104.13 | 104.95 | 103.31 |
Mar 12, 2024 | 103.95 | -0.66 | -0.63% | 104.61 | 105.21 | 103.81 |
Mar 11, 2024 | 104.05 | 2.16 | 2.12% | 101.89 | 104.21 | 101.81 |
Mar 8, 2024 | 101.57 | -0.44 | -0.43% | 102.01 | 102.45 | 101.17 |
Mar 7, 2024 | 102.21 | 2.80 | 2.82% | 99.41 | 102.37 | 99.41 |
Mar 6, 2024 | 101.25 | 1.06 | 1.06% | 100.19 | 101.41 | 99.93 |
Mar 5, 2024 | 100.79 | 0.24 | 0.24% | 100.55 | 101.49 | 99.97 |
Mar 4, 2024 | 100.13 | -0.32 | -0.32% | 100.45 | 101.11 | 99.89 |
Mar 1, 2024 | 100.83 | 0.66 | 0.66% | 100.17 | 101.03 | 99.89 |
Feb 29, 2024 | 100.05 | -1.76 | -1.73% | 101.81 | 101.81 | 99.99 |
Feb 28, 2024 | 101.81 | -0.70 | -0.68% | 102.51 | 103.29 | 101.73 |
Feb 27, 2024 | 103.05 | 1.24 | 1.22% | 101.81 | 103.33 | 101.81 |
Feb 26, 2024 | 102.45 | 0.36 | 0.35% | 102.09 | 103.47 | 101.97 |
Feb 23, 2024 | 102.19 | 2.41 | 2.42% | 99.78 | 102.41 | 99.78 |
Feb 22, 2024 | 100.03 | -0.16 | -0.16% | 100.19 | 100.23 | 98.09 |
Feb 21, 2024 | 100.91 | -0.10 | -0.10% | 101.01 | 101.63 | 100.53 |
Feb 20, 2024 | 101.91 | -0.94 | -0.91% | 102.85 | 104.13 | 101.91 |
AstraZeneca PLC - GBP Events
Time (UTC) | Country | Event |
---|---|---|
Friday, March 22, 2024 | ||
Time (UTC) 10:59 | Country GB
| Event AstraZeneca PLC ESG 2023 Highlights Summary Call AstraZeneca PLC ESG 2023 Highlights Summary CallForecast -Previous - |
Thursday, April 25, 2024 | ||
Time (UTC) 06:00 | Country GB
| Event Q1 2024 AstraZeneca PLC Earnings Release Q1 2024 AstraZeneca PLC Earnings ReleaseForecast -Previous - |
Friday, April 26, 2024 | ||
Time (UTC) 13:30 | Country GB
| Event AstraZeneca PLC Annual Shareholders Meeting AstraZeneca PLC Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 44351 | 37417 | 26617 | 24384 | 22090 |
Revenue | 44351 | 37417 | 26617 | 24384 | 22090 |
Cost of Revenue, Total | 8649 | 9542 | 5270 | 4824 | 4246 |
Gross Profit | 35702 | 27875 | 21347 | 19560 | 17844 |
Total Operating Expense | 40594 | 36361 | 21455 | 21460 | 18703 |
Selling/General/Admin. Expenses, Total | 13512 | 11519 | 9338 | 8964 | 8479 |
Research & Development | 9612 | 8519 | 6094 | 5320 | 5266 |
Depreciation / Amortization | 4094 | 3044 | 1897 | 1812 | 1945 |
Unusual Expense (Income) | 5071 | 3846 | -763 | 863 | -953 |
Other Operating Expenses, Total | -344 | -109 | -381 | -323 | -280 |
Operating Income | 3757 | 1056 | 5162 | 2924 | 3387 |
Interest Income (Expense), Net Non-Operating | -815 | -819 | -716 | -766 | -775 |
Other, Net | -441 | -502 | -530 | -610 | -619 |
Net Income Before Taxes | 2501 | -265 | 3916 | 1548 | 1993 |
Net Income After Taxes | 3293 | 115 | 3144 | 1227 | 2050 |
Minority Interest | -5 | -3 | 52 | 108 | 105 |
Net Income Before Extra. Items | 3288 | 112 | 3196 | 1335 | 2155 |
Net Income | 3288 | 112 | 3196 | 1335 | 2155 |
Income Available to Common Excl. Extra. Items | 3288 | 112 | 3196 | 1335 | 2155 |
Income Available to Common Incl. Extra. Items | 3288 | 112 | 3196 | 1335 | 2155 |
Dilution Adjustment | 0 | 0 | |||
Diluted Net Income | 3288 | 112 | 3196 | 1335 | 2155 |
Diluted Weighted Average Shares | 1560 | 1427 | 1313 | 1301 | 1267 |
Diluted EPS Excluding Extraordinary Items | 2.10769 | 0.07849 | 2.43412 | 1.02613 | 1.70087 |
Dividends per Share - Common Stock Primary Issue | 2.89361 | 2.84245 | 2.83031 | 2.89446 | 2.74532 |
Diluted Normalized EPS | 4.04679 | 2.22705 | 1.88804 | 1.48501 | 0.85399 |
Interest Expense (Income) - Net Operating | 0 | 0 | |||
Total Extraordinary Items |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 11416 | 10879 | 11207 | 10982 | 10771 |
Revenue | 11416 | 10879 | 11207 | 10982 | 10771 |
Cost of Revenue, Total | 1925 | 1782 | 2417 | 2118 | 1904 |
Gross Profit | 9491 | 9097 | 8790 | 8864 | 8867 |
Total Operating Expense | 8960 | 8330 | 10113 | 9737 | 10232 |
Selling/General/Admin. Expenses, Total | 3592 | 3196 | 3469 | 3353 | 3340 |
Research & Development | 2570 | 2299 | 2525 | 2357 | 2431 |
Depreciation / Amortization | 952 | 954 | 1034 | 979 | 983 |
Unusual Expense (Income) | -285 | 379 | 641 | 1002 | 1298 |
Other Operating Expenses, Total | 206 | -280 | 27 | -72 | 276 |
Operating Income | 2456 | 2549 | 1094 | 1245 | 539 |
Interest Income (Expense), Net Non-Operating | -368 | -287 | -316 | -323 | -292 |
Net Income Before Taxes | 2088 | 2262 | 778 | 922 | 247 |
Net Income After Taxes | 1820 | 1804 | 902 | 1642 | 360 |
Minority Interest | -2 | -1 | -1 | -2 | 0 |
Net Income Before Extra. Items | 1818 | 1803 | 901 | 1640 | 360 |
Net Income | 1818 | 1803 | 901 | 1640 | 360 |
Income Available to Common Excl. Extra. Items | 1818 | 1803 | 901 | 1640 | 360 |
Income Available to Common Incl. Extra. Items | 1818 | 1803 | 901 | 1640 | 360 |
Dilution Adjustment | |||||
Diluted Net Income | 1818 | 1803 | 901 | 1640 | 360 |
Diluted Weighted Average Shares | 1560 | 1560 | 1560 | 1559 | 1560 |
Diluted EPS Excluding Extraordinary Items | 1.16538 | 1.15577 | 0.57756 | 1.05196 | 0.23077 |
Dividends per Share - Common Stock Primary Issue | 0.91215 | 0 | 1.9694 | 0 | 0.93017 |
Diluted Normalized EPS | 1.00614 | 1.34953 | 0.90705 | 0.99743 | 0.80833 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 22593 | 26244 | 19544 | 15563 | 15591 |
Cash and Short Term Investments | 6405 | 6398 | 7992 | 6218 | 5680 |
Cash | 1411 | 1461 | 1182 | 755 | 893 |
Cash & Equivalents | 4755 | 4868 | 6650 | 4614 | 3938 |
Short Term Investments | 239 | 69 | 160 | 849 | 849 |
Total Receivables, Net | 9923 | 8795 | 5651 | 5181 | 4345 |
Accounts Receivable - Trade, Net | 7508 | 6324 | 3956 | 3813 | 2995 |
Total Inventory | 4699 | 8983 | 4024 | 3193 | 2890 |
Prepaid Expenses | 1329 | 1512 | 1735 | 865 | 1436 |
Other Current Assets, Total | 237 | 556 | 142 | 106 | 1240 |
Total Assets | 96483 | 105363 | 66729 | 61377 | 60651 |
Property/Plant/Equipment, Total - Net | 9449 | 10171 | 8917 | 8335 | 7421 |
Property/Plant/Equipment, Total - Gross | 17192 | 18495 | 17110 | 15852 | 14639 |
Accumulated Depreciation, Total | -7743 | -8324 | -8193 | -7517 | -7218 |
Goodwill, Net | 19820 | 19997 | 11845 | 11668 | 11707 |
Intangibles, Net | 39307 | 42387 | 20947 | 20833 | 21959 |
Long Term Investments | 1142 | 1237 | 1147 | 1459 | 922 |
Note Receivable - Long Term | 592 | 504 | 325 | 348 | 515 |
Other Long Term Assets, Total | 3580 | 4823 | 4004 | 3171 | 2536 |
Total Current Liabilities | 26293 | 22594 | 20307 | 18117 | 16292 |
Accounts Payable | 2550 | 2824 | 2350 | 1774 | 1720 |
Accrued Expenses | 8303 | 8079 | 4994 | 5085 | 5148 |
Notes Payable/Short Term Debt | 261 | 294 | 370 | 154 | 160 |
Current Port. of LT Debt/Capital Leases | 5281 | 1599 | 2016 | 1856 | 1594 |
Other Current Liabilities, Total | 9898 | 9798 | 10577 | 9248 | 7670 |
Total Liabilities | 59446 | 66095 | 51107 | 48250 | 48183 |
Total Long Term Debt | 23690 | 28888 | 17994 | 16217 | 17359 |
Long Term Debt | 22965 | 28134 | 17505 | 15730 | 17359 |
Capital Lease Obligations | 725 | 754 | 489 | 487 | 0 |
Deferred Income Tax | 2944 | 6206 | 2918 | 2490 | 3286 |
Minority Interest | 21 | 19 | 16 | 1469 | 1576 |
Other Liabilities, Total | 6498 | 8388 | 9872 | 9957 | 9670 |
Total Equity | 37037 | 39268 | 15622 | 13127 | 12468 |
Common Stock | 387 | 387 | 328 | 328 | 317 |
Additional Paid-In Capital | 35155 | 35126 | 7971 | 7941 | 4427 |
Retained Earnings (Accumulated Deficit) | 1495 | 3755 | 7323 | 4858 | 7724 |
Total Liabilities & Shareholders’ Equity | 96483 | 105363 | 66729 | 61377 | 60651 |
Total Common Shares Outstanding | 1549.8 | 1549.4 | 1312.67 | 1312.14 | 1267.04 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 22501 | 22839 | 22266 | 22593 | 20224 |
Cash and Short Term Investments | 5115 | 5812 | 6462 | 6405 | 4898 |
Cash & Equivalents | 4871 | 5664 | 6232 | 6166 | 4458 |
Short Term Investments | 244 | 148 | 230 | 239 | 440 |
Total Receivables, Net | 11997 | 11932 | 10797 | 11252 | 10061 |
Accounts Receivable - Trade, Net | 11300 | 11092 | 10289 | 10521 | 9336 |
Total Inventory | 5292 | 5051 | 4967 | 4699 | 5078 |
Other Current Assets, Total | 97 | 44 | 40 | 237 | 187 |
Total Assets | 96086 | 96543 | 96687 | 96483 | 94185 |
Property/Plant/Equipment, Total - Net | 9700 | 9624 | 9599 | 9449 | 9227 |
Goodwill, Net | 19939 | 19960 | 20001 | 19820 | 19707 |
Intangibles, Net | 37687 | 38326 | 39291 | 39307 | 39585 |
Long Term Investments | 1290 | 1143 | 1234 | 1142 | 1102 |
Note Receivable - Long Term | 761 | 752 | 682 | 835 | 792 |
Other Long Term Assets, Total | 4208 | 3899 | 3614 | 3337 | 3548 |
Total Current Liabilities | 28588 | 26375 | 24860 | 26293 | 24850 |
Payable/Accrued | 20542 | 19738 | 19210 | 19040 | 17694 |
Notes Payable/Short Term Debt | 331 | 271 | 568 | 261 | 584 |
Current Port. of LT Debt/Capital Leases | 5276 | 4516 | 3289 | 5281 | 5034 |
Other Current Liabilities, Total | 2439 | 1850 | 1793 | 1711 | 1538 |
Total Liabilities | 58889 | 59151 | 60898 | 59446 | 59051 |
Total Long Term Debt | 22969 | 25051 | 27646 | 23690 | 23681 |
Long Term Debt | 22225 | 24329 | 26916 | 22965 | 23013 |
Capital Lease Obligations | 744 | 722 | 730 | 725 | 668 |
Deferred Income Tax | 2752 | 2800 | 2795 | 2944 | 3479 |
Minority Interest | 24 | 24 | 22 | 21 | 20 |
Other Liabilities, Total | 4556 | 4901 | 5575 | 6498 | 7021 |
Total Equity | 37197 | 37392 | 35789 | 37037 | 35134 |
Common Stock | 387 | 387 | 387 | 387 | 387 |
Additional Paid-In Capital | 35166 | 35163 | 35159 | 35155 | 35137 |
Retained Earnings (Accumulated Deficit) | 1644 | 1842 | 243 | 1495 | -390 |
Total Liabilities & Shareholders’ Equity | 96086 | 96543 | 96687 | 96483 | 94185 |
Total Common Shares Outstanding | 1549.91 | 1549.88 | 1549.85 | 1549.8 | 1549.51 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 2501 | -265 | 3916 | 1548 | 1993 |
Cash From Operating Activities | 9808 | 5963 | 4799 | 2969 | 2618 |
Cash From Operating Activities | 5480 | 6530 | 3149 | 3762 | 3753 |
Non-Cash Items | 542 | 141 | -332 | -103 | -1276 |
Cash Taxes Paid | 1623 | 1743 | 1562 | 1118 | 537 |
Cash Interest Paid | 849 | 721 | 733 | 774 | 676 |
Changes in Working Capital | 1285 | -443 | -1934 | -2238 | -1852 |
Cash From Investing Activities | -2960 | -11058 | -285 | -657 | 963 |
Capital Expenditures | -2571 | -2200 | -2606 | -2460 | -1371 |
Other Investing Cash Flow Items, Total | -389 | -8858 | 2321 | 1803 | 2334 |
Cash From Financing Activities | -6823 | 3649 | -2203 | -1765 | -2044 |
Financing Cash Flow Items | -1047 | -178 | -101 | 4 | -67 |
Total Cash Dividends Paid | -4364 | -3856 | -3572 | -3592 | -3484 |
Issuance (Retirement) of Stock, Net | 29 | 29 | 30 | 3525 | 34 |
Issuance (Retirement) of Debt, Net | -1441 | 7654 | 1440 | -1702 | 1473 |
Foreign Exchange Effects | -80 | -62 | 12 | 5 | -38 |
Net Change in Cash | -55 | -1508 | 2323 | 552 | 1499 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 2262 | 2501 | 1723 | 800 | 553 |
Cash From Operating Activities | 3133 | 9808 | 7410 | 4480 | 3232 |
Cash From Operating Activities | 1502 | 5480 | 4000 | 2666 | 1309 |
Non-Cash Items | -391 | 542 | 172 | 15 | -12 |
Cash Taxes Paid | 225 | 1623 | 1335 | 1006 | 228 |
Cash Interest Paid | 257 | 849 | 608 | 386 | 194 |
Changes in Working Capital | -240 | 1285 | 1515 | 999 | 1382 |
Cash From Investing Activities | -1246 | -2960 | -2711 | -968 | -168 |
Capital Expenditures | -1470 | -2571 | -2017 | -906 | -363 |
Other Investing Cash Flow Items, Total | 224 | -389 | -694 | -62 | 195 |
Cash From Financing Activities | -2031 | -6823 | -6465 | -5035 | -3740 |
Financing Cash Flow Items | -840 | -1047 | -1047 | -997 | -997 |
Total Cash Dividends Paid | -3047 | -4364 | -4364 | -2971 | -2971 |
Issuance (Retirement) of Stock, Net | 4 | 29 | 11 | 8 | 5 |
Issuance (Retirement) of Debt, Net | 1852 | -1441 | -1065 | -1075 | 223 |
Foreign Exchange Effects | -11 | -80 | -86 | -35 | -9 |
Net Change in Cash | -155 | -55 | -1852 | -1558 | -685 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.5096 | 100893184 | 1200 | 2023-01-31 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 4.1998 | 65092368 | 768 | 2023-01-31 | LOW |
Investor AB | Private Equity | 3.3298 | 51608948 | 608 | 2023-01-31 | LOW |
Capital Research Global Investors | Investment Advisor | 3.1211 | 48374655 | -165706 | 2023-06-15 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.8719 | 44511608 | 671315 | 2023-06-15 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 2.2154 | 34336042 | 875 | 2023-10-01 | LOW |
Capital World Investors | Investment Advisor | 1.8709 | 28997204 | 474010 | 2023-06-15 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 1.3307 | 20624979 | 125455 | 2023-10-01 | LOW |
BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 1.1707 | 18144143 | -35319 | 2023-10-01 | LOW |
GQG Partners, LLC | Investment Advisor | 1.0711 | 16600615 | 66511 | 2023-06-15 | MED |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.9319 | 14443159 | -63166 | 2023-10-01 | LOW |
State Street Global Advisors (UK) Ltd. | Investment Advisor/Hedge Fund | 0.7607 | 11789511 | 0 | 2023-10-01 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 0.6104 | 9460420 | 45825 | 2023-10-01 | LOW |
Nuveen LLC | Pension Fund | 0.5685 | 8811257 | 378713 | 2023-06-15 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5618 | 8707369 | 257289 | 2023-06-15 | LOW |
Aviva Investors Global Services Limited | Investment Advisor/Hedge Fund | 0.5266 | 8162319 | -429899 | 2023-10-01 | LOW |
Handelsbanken Kapitalförvaltning AB | Investment Advisor/Hedge Fund | 0.5212 | 8078066 | 1670 | 2023-09-30 | LOW |
M&G Investment Management Ltd. | Investment Advisor | 0.4752 | 7364510 | 948 | 2023-10-01 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.4611 | 7146065 | 10590 | 2023-10-01 | LOW |
Union Investment Privatfonds GmbH | Investment Advisor | 0.4173 | 6467102 | 30000 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
AstraZeneca - GBP Company profile
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a patient-focused biopharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The Company is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The Company has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, AstraZeneca plc revenues increased 41% to $37.42B. Net income decreased 96% to $112M. Revenues reflect Farxiga segment increase of 53% to $3B, Calquenc segment increase from $522M to $1.24B, Tagrisso segment increase of 16% to $5.02B, United States segment increase of 35% to $12.05B, United Kingdom segment increase of 86% to $3.25B, Sweden segment increase from $1.03B to $2.32B.
Industry: | Pharmaceuticals (NEC) |
1 Francis Crick Avenue
CAMBRIDGE
CAMBRIDGESHIRE CB2 0AA
GB
Income Statement
- Annual
- Quarterly
News
Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?
UK banks will be in the spotlight in the week ahead as the European earnings season continues
16:38, 16 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com